Hodgkin lymphoma - Clinical

 
Dennis A. Eichenauer, Stefanie Kreissl, Ina Bühnen, et al.
 
The authors of the abstract conclude: 
This analysis includes the largest cohort of patients with advanced NLPHL treated within a controlled randomized study reported to date. It indicates an excellent outcome for PET-2-negative patients after a total of only 4 cycles of escalated BEACOPP. The outcome of PET-2-positive patients appears to be worse and the addition of rituximab to escalated BEACOPP did not improve it. Overall, individualized PET-2-guided treatment with escalated BEACOPP is feasible and effective in advanced-stage NLPHL. However, baseline identification of individual risk factors is warranted to further develop the treatment for this patient group.
————————————————————————————————————————————————————————
 
 
Julia Driessen, Otto Visser, Josée M. Zijlstra, et al.
 
The authors of the abstract conclude: 
Overall, 5-year CRS increased with each year survived after diagnosis, with the most marked increases for patients who survived the first 3 years post-diagnosis, especially in stage III/IV patients. This finding suggests that most patients who survive after this time have low EM. Patients up to age 50 had low to minimal EM over the follow-up period, suggesting that their survival expectations are considered similar to comparable groups from the general population. Age 50 or above, however, remains an important prognostic factor over time, because it was associated with persistent EM that could be ascribed to late treatment-related toxicity, secondary malignancies, or late relapses. Our study findings can be used to plan tailored surveillance and follow-up activities.
————————————————————————————————————————————————————————
 
 
Stefanie Kreissl, Helen Goergen, Carsten Kobe, et al.
 
The authors of the abstract conclude: 
The prolonged follow-up data establish the non-inferiority of only 4x eBEACOPP not only compared to 8 but also to 6x eBEACOPP in terms of PFS in early responding patients. The OS benefit of 4x eBEACOPP due to less treatment-related toxicity and SPMN is however less pronounced over 6x eBEACOPP than over the former standard of 8x eBEACOPP. Our results confirm the PET-2-guided treatment reduction to only 4 cycles eBEACOPP for well responding patients as a short, highly effective and very safe treatment strategy in advanced-stage HL.
————————————————————————————————————————————————————————
 
 
Julia Driessen, Otto Visser, Josée M. Zijlstra, et al.
 
The authors of the abstract conclude: 
The population-level survival of cHL patients aged ≥60 years in modern clinical practice is still far from the life expectancy of comparable groups from the general population. Although most patients are treated with ABVD or CHOP as per guideline recommendations, the majority did not complete the recommended treatment cycles, mostly due to toxicity or comorbidity. Therefore, less toxic regimens that do not compromise treatment efficacy are needed to reduce EM in older cHL patients.
————————————————————————————————————————————————————————
 
 
Christine Mauz-Körholz, Thierry Leblanc, Maurizio Mascarin, et al.
 
The authors of the abstract conclude: 
This nivolumab and BV-based, risk-stratified, response-adapted salvage strategy had high CMR rates and was well tolerated with no new safety signals in CAYA with R/R cHL. The majority of patients did not require bendamustine intensification. Additional follow-up is needed to confirm the durability of disease control.
————————————————————————————————————————————————————————